Andrew J. Pierce
Senior Vice President
Also affiliated: AstraZeneca (United Kingdom) (2015–2024); University of North Carolina at Chapel Hill (1992–2020); The Graduate Center, CUNY (2010); Babraham Institute (2024); Memorial Sloan Kettering Cancer Center (1999–2005); University of Kentucky (2004–2014); University of South Carolina (2010); Duke University (1997); Cornell University (1999–2002); Durham Technical Community College (1997); Markey Cancer Center (2004–2020); University of Florida (2016); Humboldt-Universität zu Berlin (2005); Syngenta (United Kingdom) (2025); ScienceSouth (2021); AstraZeneca (France) (2018–2020); AstraZeneca (Singapore) (2018–2021); AstraZeneca (Brazil) (2021); Babraham Bioscience Technologies (United Kingdom) (2024); Dana-Farber Cancer Institute (2005); AstraZeneca (Japan) (2018); Altimmune (United States) (2015); AstraZeneca (Finland) (2021); AstraZeneca (United States) (2018); Napp Pharmaceuticals (United Kingdom) (2018); US Biologic (United States) (2021–2025); UNC Lineberger Comprehensive Cancer Center (1992); King Mongkut's University of Technology Thonburi (2011–2025); Charité - Universitätsmedizin Berlin (2005); Syngenta (Switzerland) (2025)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Andrew J. Pierce's research focuses on cancer treatment and pharmacology, particularly investigating novel therapeutic agents and their mechanisms of action. He has been involved in clinical trials for agents like ceralasertib, an ATR kinase inhibitor, exploring its efficacy in combination with chemotherapy regimens such as carboplatin and paclitaxel for advanced and refractory solid tumors. His work also examines the role of DNA damage response pathways in predicting treatment outcomes, with a specific interest in biomarkers like Schlafen11 (SLFN11).
Further research by Pierce explores the intersection of immunotherapy and DNA repair mechanisms. This includes investigating how ATR inhibitors can enhance cancer immunotherapy by modulating the tumor microenvironment. Additionally, his publications address the development and application of bispecific antibodies, such as those targeting PD-1 and LAG-3 on T cells to promote anti-tumor activity, and dual-targeting Humabody therapeutics for specific tumor types like PSMA-positive cancers. His work also involves the development and application of mass spectrometry for quantifying pharmacodynamic biomarkers related to kinase inhibition, such as ATM kinase.
Metrics
- h-index: 34
- Publications: 171
- Citations: 7,675
Selected Publications
-
Quantifying Resilience in Single-Host/Single-Virus Infections (2025)
Collaboration Network
Top Collaborators
- Supplementary Figures 1-14; Supplementary Tables 1-3 from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- supplementary figure legends from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 13 shared publications
- Supplementary Figures 1-14; Supplementary Tables 1-3 from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- supplementary figure legends from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 13 shared publications
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 12 shared publications
- Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
- Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
- Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
- Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts
- PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Similar Researchers
Based on overlapping research topics